This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Dynamic Allocation Modular Sequential Trial of A...
Clinical trial

A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)

Read time: 1 mins
Last updated:1st Jun 2016

The goal of this clinical research study is to find out if the combination of ARN-509, abiraterone acetate, and prednisone can be given with either ipilimumab or cabazitaxel plus carboplatin to control metastatic CRPC. The safety and effectiveness of these drug combinations and their effect on the immune system will also be studied.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)
Estimated Enrollment: 265
Study Start Date: June 2016
Estimated Primary Completion Date: June 2020 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
ARN-509 + Abiraterone + Prednisone
- Experimental: ARN-509 + Abiraterone + Prednisone + Ipilimumab
- Experimental: ARN-509+Abiraterone+Pred+Cabazitaxel+Carbo

Category Value
Study start date 2016-06-01

View full details